ALDA Pharmaceuticals Corp.-Bulletin: Swine Flu

Mon. April 27, 2009; Posted: 07:31 PM

VANCOUVER, BRITISH COLUMBIA, Apr 27, 2009 (Marketwire via COMTEX) -- APH | Quote | Chart | News | PowerRating -- ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) -

The current "swine flu", which is creating concerns about the possibility of a new pandemic, is caused by a new form of the Influenza A virus which shows characteristics of swine, avian and human viruses. Swine flu does not normally infect humans but a major pandemic occurred in 1918 when approximately 500 million people were infected worldwide and 50 million died. Since then, there have been other occurrences of swine flu but, prior to the current outbreak, only a small number of people were infected.

Historically, there have been approximately 3 influenza pandemics in each century for the last 300 years. The most recent ones were the Asian Flu in 1957 and the Hong Kong Flu in 1968. In recent years, the global focus for a pandemic has shifted to the H5N1 bird flu virus, which has spread from poultry to humans, especially in Asia but The World Health Organization has now also identified swine influenza as a potential source of a human flu pandemic.

Health organizations in Canada and the US have published recommendations on how to reduce the transmission of swine flu. These include washing your hands thoroughly with soap and warm water or hand sanitizer, covering your mouth when coughing and sneezing, keep doing what you normally do but stay home if you're sick and talk to your doctor if you experience flu-like symptoms.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. T36(R) has been proven to be effective against the H1N1 and H3N2 strains of swine flu and against SARS-like viruses. The company trades on the TSX Venture Exchange under the symbol "APH", and is quoted on the OTCBB under the symbol "APCSF".

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

SOURCE: ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.
Peter Chen
Distribution & Sales Contact
(604) 521-8300 Ext. 3
(604) 521-8322 (FAX)
peter_chen@aldacorp.com
www.aldacorp.com
ALDA Pharmaceuticals Corp.
Scott Young
Investor Relations Contact
(604) 288-7222
syoung@freeformcom.com